Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination

William Mulley, Kumar Visvanathan, Aeron C Hurt, Fiona G Brown, Kevan R Polkinghorne, Tasoula Mastorakos, Michelle C Lewicki, Rhonda L Stuart, Sven-Jean Tan, Roy Chean, Peter Kerr, John Kanellis

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Abstract

In late 2009 transplant organizations recommended that kidney recipients be vaccinated for pandemic H1N1 influenza (pH1N1); however, the vaccine efficacy was unknown. We had offered a monovalent non-adjuvanted pH1N1 vaccine to transplant recipients. Here we compared the pre- and post-vaccination seroresponses of 151 transplant recipients to that of 71 hemodialysis patients and 30 healthy controls. Baseline seroprotection was similar between groups but was significantly different at 1 month (44, 56, and 87 , respectively). Seroconversion was significantly less common for transplant recipients (32 ) than dialysis patients (45 ) and healthy controls (77 ). After adjusting for age and gender, dialysis patients were significantly more likely (2.7-fold) to achieve new seroprotection than transplant recipients. The likelihood of seroprotection in transplant recipients was significantly reduced by mycophenolate use (adjusted odds ratio 0.24), in a dose-dependent manner, and by reduced eGFR (adjusted odds ratio 0.16 for worst to best). Seroprotection and geometric mean antibody titers increased substantially in 49 transplant recipients who subsequently received the 2010 seasonal influenza vaccine. Thus, patients requiring renal replacement therapy had reduced seroresponses to vaccination with the monovalent vaccine compared with healthy controls. Transplant recipient responses were further reduced if they were receiving mycophenolate or had significantly lower graft function.
Original languageEnglish
Pages (from-to)212 - 219
Number of pages8
JournalKidney International
Volume82
Issue number2
DOIs
Publication statusPublished - 2012

Cite this

Mulley, William ; Visvanathan, Kumar ; Hurt, Aeron C ; Brown, Fiona G ; Polkinghorne, Kevan R ; Mastorakos, Tasoula ; Lewicki, Michelle C ; Stuart, Rhonda L ; Tan, Sven-Jean ; Chean, Roy ; Kerr, Peter ; Kanellis, John. / Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. In: Kidney International. 2012 ; Vol. 82, No. 2. pp. 212 - 219.
@article{44723c1371664b74826a9fa3cbf392e6,
title = "Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination",
abstract = "In late 2009 transplant organizations recommended that kidney recipients be vaccinated for pandemic H1N1 influenza (pH1N1); however, the vaccine efficacy was unknown. We had offered a monovalent non-adjuvanted pH1N1 vaccine to transplant recipients. Here we compared the pre- and post-vaccination seroresponses of 151 transplant recipients to that of 71 hemodialysis patients and 30 healthy controls. Baseline seroprotection was similar between groups but was significantly different at 1 month (44, 56, and 87 , respectively). Seroconversion was significantly less common for transplant recipients (32 ) than dialysis patients (45 ) and healthy controls (77 ). After adjusting for age and gender, dialysis patients were significantly more likely (2.7-fold) to achieve new seroprotection than transplant recipients. The likelihood of seroprotection in transplant recipients was significantly reduced by mycophenolate use (adjusted odds ratio 0.24), in a dose-dependent manner, and by reduced eGFR (adjusted odds ratio 0.16 for worst to best). Seroprotection and geometric mean antibody titers increased substantially in 49 transplant recipients who subsequently received the 2010 seasonal influenza vaccine. Thus, patients requiring renal replacement therapy had reduced seroresponses to vaccination with the monovalent vaccine compared with healthy controls. Transplant recipient responses were further reduced if they were receiving mycophenolate or had significantly lower graft function.",
author = "William Mulley and Kumar Visvanathan and Hurt, {Aeron C} and Brown, {Fiona G} and Polkinghorne, {Kevan R} and Tasoula Mastorakos and Lewicki, {Michelle C} and Stuart, {Rhonda L} and Sven-Jean Tan and Roy Chean and Peter Kerr and John Kanellis",
year = "2012",
doi = "10.1038/ki.2012.106",
language = "English",
volume = "82",
pages = "212 -- 219",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Elsevier",
number = "2",

}

Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. / Mulley, William; Visvanathan, Kumar; Hurt, Aeron C; Brown, Fiona G; Polkinghorne, Kevan R; Mastorakos, Tasoula; Lewicki, Michelle C; Stuart, Rhonda L; Tan, Sven-Jean; Chean, Roy; Kerr, Peter; Kanellis, John.

In: Kidney International, Vol. 82, No. 2, 2012, p. 212 - 219.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination

AU - Mulley, William

AU - Visvanathan, Kumar

AU - Hurt, Aeron C

AU - Brown, Fiona G

AU - Polkinghorne, Kevan R

AU - Mastorakos, Tasoula

AU - Lewicki, Michelle C

AU - Stuart, Rhonda L

AU - Tan, Sven-Jean

AU - Chean, Roy

AU - Kerr, Peter

AU - Kanellis, John

PY - 2012

Y1 - 2012

N2 - In late 2009 transplant organizations recommended that kidney recipients be vaccinated for pandemic H1N1 influenza (pH1N1); however, the vaccine efficacy was unknown. We had offered a monovalent non-adjuvanted pH1N1 vaccine to transplant recipients. Here we compared the pre- and post-vaccination seroresponses of 151 transplant recipients to that of 71 hemodialysis patients and 30 healthy controls. Baseline seroprotection was similar between groups but was significantly different at 1 month (44, 56, and 87 , respectively). Seroconversion was significantly less common for transplant recipients (32 ) than dialysis patients (45 ) and healthy controls (77 ). After adjusting for age and gender, dialysis patients were significantly more likely (2.7-fold) to achieve new seroprotection than transplant recipients. The likelihood of seroprotection in transplant recipients was significantly reduced by mycophenolate use (adjusted odds ratio 0.24), in a dose-dependent manner, and by reduced eGFR (adjusted odds ratio 0.16 for worst to best). Seroprotection and geometric mean antibody titers increased substantially in 49 transplant recipients who subsequently received the 2010 seasonal influenza vaccine. Thus, patients requiring renal replacement therapy had reduced seroresponses to vaccination with the monovalent vaccine compared with healthy controls. Transplant recipient responses were further reduced if they were receiving mycophenolate or had significantly lower graft function.

AB - In late 2009 transplant organizations recommended that kidney recipients be vaccinated for pandemic H1N1 influenza (pH1N1); however, the vaccine efficacy was unknown. We had offered a monovalent non-adjuvanted pH1N1 vaccine to transplant recipients. Here we compared the pre- and post-vaccination seroresponses of 151 transplant recipients to that of 71 hemodialysis patients and 30 healthy controls. Baseline seroprotection was similar between groups but was significantly different at 1 month (44, 56, and 87 , respectively). Seroconversion was significantly less common for transplant recipients (32 ) than dialysis patients (45 ) and healthy controls (77 ). After adjusting for age and gender, dialysis patients were significantly more likely (2.7-fold) to achieve new seroprotection than transplant recipients. The likelihood of seroprotection in transplant recipients was significantly reduced by mycophenolate use (adjusted odds ratio 0.24), in a dose-dependent manner, and by reduced eGFR (adjusted odds ratio 0.16 for worst to best). Seroprotection and geometric mean antibody titers increased substantially in 49 transplant recipients who subsequently received the 2010 seasonal influenza vaccine. Thus, patients requiring renal replacement therapy had reduced seroresponses to vaccination with the monovalent vaccine compared with healthy controls. Transplant recipient responses were further reduced if they were receiving mycophenolate or had significantly lower graft function.

UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22495292

U2 - 10.1038/ki.2012.106

DO - 10.1038/ki.2012.106

M3 - Article

VL - 82

SP - 212

EP - 219

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -